Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies

Abstract FGFR inhibitors have been developed to inhibit FGFR activation and signal transduction; notwithstanding, currently the selection of intrahepatic cholangiocarcinoma (iCCA) patients for these drugs only relies on the detection of FGFR2 genetic alterations (GAs) in tumor tissues or circulating...

Повний опис

Бібліографічні деталі

Автори:	Giovanni Brandi, Valeria Relli, Marzia Deserti, Andrea Palloni, Valentina Indio, Annalisa Astolfi, Salvatore Serravalle, Alessandro Mattiaccio, Francesco Vasuri, Deborah Malvi, Chiara Deiana, Maria Abbondanza Pantaleo, Matteo Cescon, Alessandro Rizzo, Masaru Katoh, Simona Tavolari
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Nature Portfolio 2024-02-01
Серія:	Scientific Reports
Онлайн доступ:	https://doi.org/10.1038/s41598-024-52991-8
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!